MedPath
NMPA Approval

Hydrotalcite Suspension

国药准字H20243983

June 11, 2024

Drug Information

铝碳酸镁混悬液

口服混悬剂

10ml:1g

化学药品

June 11, 2024

Company Information

Applicant Company

浙江省杭州市临平区东湖街道新天路101号

Manufacturing Company

浙江省金华市婺城区汤溪镇永湖街788号

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

铝碳酸镁混悬液 - NMPA 批准文号 | MedPath